Target intelligence / Profile preview

Proto-oncogene protein Wnt-3 (Wnt3)

Target: Wnt3
Molecular classification: Secreted signaling protein, Ligand, Morphogen, Member of the Wnt family

Overview

Proto-oncogene protein Wnt-3 (Wnt3) is a highly conserved, secreted signaling ligand belonging to the Wnt family of morphogens. It plays a central role in the activation of the canonical Wnt/β-catenin pathway, mediating cell fate determination, proliferation, and differentiation during embryonic development. Wnt3 binds to Frizzled and LRP5/6 membrane receptors, triggering a cascade that stabilizes β-catenin and drives transcription of Wnt target genes. Dysregulation or overexpression of Wnt3 is implicated in the initiation, progression, and resistance to therapy in several human cancers. Targeting Wnt3-mediated signaling is an area of therapeutic interest, though challenges remain due to its fundamental roles in normal tissue homeostasis and development.

Other names: Proto-oncogene Wnt3Wingless-type MMTV integration site family member 3WNT3

Mechanism of action

Activation or inhibition of Wnt/β-catenin signaling pathway via ligand-receptor (Frizzled, LRP5/6) interaction; Stabilization of β-catenin and transcriptional activation of target genes

Biological functions

Signal transductionCell fate specificationCell proliferationCell differentiationEmbryonic developmentRegulation of oncogenesis

Disease associations

Cancer (breast, rectal, lung, gastric, prostate, colorectal, mantle cell lymphoma, bladder urothelial carcinoma)

Safety considerations

Broad role in stem cell maintenance, tissue homeostasis, and development raises toxicity concerns for direct targetingPotential for adverse effects on normal tissue regeneration and embryonic development

Interacting drugs

None established as currently approved or in clinical use directly targeting Wnt3 ligand; indirect modulators of the Wnt/β-catenin pathway (e.g., PORCN inhibitors) are in development, but not Wnt3-specific

Biomarkers

Overexpression of Wnt3 can serve as a prognostic biomarker in several cancers (e.g., non-small cell lung cancer, prostate cancer)

Beyond the preview

Go deeper on Proto-oncogene protein Wnt-3 (Wnt3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proto-oncogene protein Wnt-3 (Wnt3).

Explore the full profile